Consolidated Statement of Stockholders' Equity (Deficit) (USD $)	Incuron LLC [Member] Additional Paid-in Capital [Member]	Incuron LLC [Member] Noncontrolling Interest [Member]	Incuron LLC [Member]	Panacela Labs Inc [Member] Noncontrolling Interest [Member]	Panacela Labs Inc [Member]	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at at Jan. 01, 2009						$ 68,879	$ 15,805	$ 56,699,749		$ (56,246,172)		$ 538,261
Balance at (in Shares) at Jan. 01, 2009						13,775,805	3,160,974
Issuance of common stock net of offering costs							3	4,708,129				4,708,132
Issuance of common stock net of offering costs (in Shares)							543
Conversion of Preferred Shares to Common						26,330	(15,806)	(10,524)
Conversion of Preferred Shares to Common (in Shares)						5,265,883	(3,161,050)
Allocation of financing proceeds to fair value of warrants								(3,016,834)				(3,016,834)
Exercise of options						973		361,884				362,857
Exercise of options (in Shares)						194,675
Exercise of warrants						3,378		1,285,026				1,288,404
Exercise of warrants (in Shares)						675,613
Stock based compensation						1,458		2,758,988				2,760,446
Stock based compensation (in Shares)						291,532
Dividends on preferred shares										(615,351)		(615,351)
Net Loss										(12,826,409)		(12,826,409)
Balance at at Dec. 31, 2009						101,018	2	62,786,418		(69,687,932)		(6,800,494)
Balance at (in Shares) at Dec. 31, 2009						20,203,508	467
Issuance of common stock net of offering costs						14,692		12,133,212				12,147,904
Issuance of common stock net of offering costs (in Shares)						2,938,462
Conversion of Preferred Shares to Common						22,885	(2)	(22,883)
Conversion of Preferred Shares to Common (in Shares)						4,576,979	(467)
Noncontrolling interest capital contribution		3,509,564	3,509,564
Allocation of financing proceeds to fair value of warrants								(2,629,847)				(2,629,847)
Exercise of options						1,683		900,228				901,911
Exercise of options (in Shares)						336,674
Exercise of warrants						2,212		2,436,745				2,438,957
Exercise of warrants (in Shares)						442,357
Stock based compensation						2,306		4,637,844				4,640,150
Stock based compensation (in Shares)						461,196
Net Loss										(26,366,045)	(305,812)	(26,671,857)
Foreign currency translation									(30,544)		(5,879)	(36,423)
Balance at at Dec. 31, 2010						144,796		80,241,717	(30,544)	(96,053,977)	3,197,873	(12,500,135)
Balance at (in Shares) at Dec. 31, 2010						28,959,176
Issuance of common stock net of offering costs						29,363		21,840,999				21,870,362
Issuance of common stock net of offering costs (in Shares)						5,872,500
Noncontrolling interest capital contribution	176,092	2,164,282	2,340,374	9,000,066	9,000,066
Allocation of financing proceeds to fair value of warrants								(2,525,175)				(2,525,175)
Exercise of options						951		531,457				532,408
Exercise of options (in Shares)						190,255
Exercise of warrants						1,407		1,943,813				1,945,220
Exercise of warrants (in Shares)						281,411
Stock based compensation						1,544		6,656,742				6,658,286
Stock based compensation (in Shares)						308,850
Net Loss										(4,013,670)	(1,216,055)	(5,229,725)
Foreign currency translation									115,157		38,658	153,815
Balance at at Dec. 31, 2011						$ 178,061		$ 108,865,645	$ 84,613	$ (100,067,647)	$ 13,184,824	$ 22,245,496
Balance at (in Shares) at Dec. 31, 2011						35,612,192